Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer.
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
/ biosynthesis
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Proteins
/ biosynthesis
Oxidoreductases
/ biosynthesis
Prognosis
Prostate
/ metabolism
Prostatic Neoplasms
/ diagnosis
Transcription Factors
/ biosynthesis
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
02
2019
accepted:
16
07
2019
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
4
3
2020
Statut:
epublish
Résumé
Prostate cancer is the second most common cancer diagnosed in men worldwide; however, few patients are affected by clinically significant disease within their lifetime. Unfortunately, the means to discriminate between patients with indolent disease and those who progress to aggressive prostate cancer is currently unavailable, resulting in over-treatment of patients. We therefore aimed to determine biomarkers of prostate cancer that can be used in the clinic to aid the diagnosis and prognosis. Immunohistochemistry analysis was carried out on prostate cancer specimens with a range of Gleason scores. Samples were stained and analysed for intensity of the Seven Transmembrane Epithelial Antigen of the Prostate (STEAP)-1, -2, -3, -4 and the Divalent Metal Transporter 1 (DMT1) proteins to determine suitable biomarkers for classification of patients likely to develop aggressive prostate cancer. Additionally, these proteins were also analysed to determine whether any would be able to predict future relapse using Kaplan Meier analysis. Data generated demonstrated that the protein expression levels of STEAP2 correlated significantly with Gleason score; furthermore, STEAP4 was a significant predictor of relapse. This data indicates that STEAP2 could be potential prognostic candidate for use in combination with the current prostate cancer detection methods and the presence of STEAP4 could be an indicator of possible relapse.
Identifiants
pubmed: 31393902
doi: 10.1371/journal.pone.0220456
pii: PONE-D-19-03189
pmc: PMC6687176
doi:
Substances chimiques
Antigens, Neoplasm
0
DMRT1 protein
0
Neoplasm Proteins
0
Transcription Factors
0
Oxidoreductases
EC 1.-
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220456Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14523-8
pubmed: 10588738
J Biol Chem. 2002 Sep 27;277(39):36689-96
pubmed: 12095985
Lab Invest. 2002 Nov;82(11):1573-82
pubmed: 12429817
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2284-9
pubmed: 12606722
J Urol. 1992 Mar;147(3 Pt 2):837-40
pubmed: 1371558
Oncogene. 2005 Jul 21;24(31):4934-45
pubmed: 15897894
Blood. 2006 Aug 15;108(4):1388-94
pubmed: 16609065
Gut. 2006 Oct;55(10):1449-60
pubmed: 16641131
Cell. 2007 May 4;129(3):537-48
pubmed: 17482547
Cancer Res. 2007 Jun 15;67(12):5798-805
pubmed: 17575147
World J Gastroenterol. 2007 Sep 21;13(35):4725-36
pubmed: 17729394
Cancer Res. 2010 Jul 15;70(14):5818-28
pubmed: 20587517
Physiol Genomics. 2011 Feb 11;43(3):110-20
pubmed: 21081660
Mol Med Rep. 2011 May-Jun;4(3):519-23
pubmed: 21468601
Cancer Res. 2012 May 1;72(9):2285-93
pubmed: 22419665
Haematologica. 2012 Dec;97(12):1826-35
pubmed: 22689674
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
Biol Cell. 2012 Nov;104(11):641-57
pubmed: 22804687
Biochem Biophys Res Commun. 2012 Dec 14;429(3-4):148-55
pubmed: 23142226
Exp Cell Res. 2013 Oct 15;319(17):2617-26
pubmed: 23916873
Histopathology. 2013 Nov;63(5):678-85
pubmed: 24025158
Urol Oncol. 2014 Jan;32(1):53.e23-9
pubmed: 24239460
Prostate Int. 2014 Sep;2(3):133-9
pubmed: 25325025
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Indian J Med Res. 2014 Oct;140(4):507-12
pubmed: 25488444
Curr Oncol. 2015 Feb;22(1):10-2
pubmed: 25684983
BMC Med. 2015 Jul 30;13:171
pubmed: 26224061
Contemp Oncol (Pozn). 2015;19(6):471-3
pubmed: 26843845
Diagn Pathol. 2016 Jul 11;11(1):63
pubmed: 27401406
Oncology (Williston Park). 1997 Apr;11(4):475-82, 485; discussion 485-6, 489
pubmed: 9130271